Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride

作者：Hojjat Ahmadzadehfar, Stefanie Zimbelmann, Anna Yordanova, Rolf Fimmers, Stefan Kürpig, Elisabeth Eppard, Florian Gaertner, Xiao X. Wei, Stefan Hauser, Markus Essler · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.15698 · 被引用次数：69 · 研究领域：Prostate Cancer Treatment and Research、Radiopharmaceutical Chemistry and Applications、Bone health and treatments

// Hojjat Ahmadzadehfar 1,* , Stefanie Zimbelmann 1,* , Anna Yordanova 1 , Rolf Fimmers 2 , Stefan Kürpig 1 , Elisabeth Eppard 1 , Florian C. Gaertner 1 , Xiao Wei 1 , Stefan Hauser 3 and Markus Essler 1 1 Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany 2 Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany 3 Department of Urology, University Hospital Bonn, Bonn, Germany * These authors have contributed equally to this work Correspondence to: Hojjat Ahmadzadehfar, email: // Keywords : Lu-PSMA-617; hematotoxicity; radium-223; prostate cancer; radioligand therapy Received : December 06, 2016 Accepted : February 07, 2017 Published : February 25, 2017 Abstract Radioligand therapy with 177 Lu-PSMA-617 is an innovative and effective therapy for castrate-resistant metastatic prostate cancer patients. For patients with symptomatic bone metastases without visceral metastases, the guidelines recommend radionuclide therapy with 223 Ra-dichloride as a single therapeutic agent or in combination with hormone therapy. The aim of this study was to evaluate the safety of repeated cycles of 177 Lu-PSMA-617 after exposure to more cycles of 223 Ra. Forty-nine patients were treated with three cycles of Lu-PSMA-617 divided into two groups subjected to a history of therapy with 223 Ra. Group 1 included 20 patients, who had received therapy with 223 Ra prior to Lu-PSMA-617 therapy. Group 2, which was the control group regarding hemat...